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S U M M A R Y 
This publication contains the second series of reports by the 
Scientific Committee on Cosmetology on : 
- the use of some hair dyes 
- the use of 1,3-Bis (Hydroximethyl) imidazolidine-2-thione in 
haii—care preparations 
- supplementary opinion on boric acid 
- the use of 4,4-dimethyl-1,3-oxazolidine as a preservative 
- the use of 1,2-dibromo-2,4-dicyanobutane as a preservative 
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INTRODUCTION 
The Scientific Committee on Cosmetology was set up by Commission 
Decision 78/45/EEC of 19 December 1977 (OJ N° L 13 of 17 January 1978, 
p. 24) in order to provide the Commission with informed opinions on any 
scientific and technical problems arising in connection with cosmetic 
products, and in particular on the substances used in their manufacture, 
on their composition and on the conditions for their use. 
The members of the Committee are independent scientists highly qualified 
in the fields of medicine, toxicology, biology, chemistry or other 
simi lar disciplines. 
The Committee is serviced by the Directorate-general for the environment, 
consumer protection and nuclear safety. 
This volume contains a collection of the Committee's second reports setting 
out the opinions it delivered on the dates given in the headings. 
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REPORT 
of 
THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
CONCERNING SOME HAIR DYES 
(Opinion delivered on 2 September 1980) 
THE COMMITTEE'S MANDATE 
To give its opinion on the use as hair dyes of the following substances: 
1-methoxy-2/4-diaminobenzene (2,4-diamino-aniso le) 
1 -met hoxy-2, 5—di ami nobenzene (2., 5—di ami no-ani so le) 
1y4-diamino-2-nitrobenzene (2 NPPD) 
1,2-diamino-4-nitrobenzene (4 NOPD) 
1-methyl-2y4-diaminobenzene (2., 4-di ami no-toluene) 
1-methyl-2y 5-diaminobenzene (2,5-diamino-toluene) 
1_,2-d i am i nobenzene (o-pheny l enediamine) 
ìj 3-diaminobenzene (m-phenylenediamine) 
1^, 4-di ami nobenzene (p-phenylenediamine) 
1-hydroxy-2-amino-4-nitrobenzene (2-amino-4-nitrophenol) 
1-hydroxy-2-amino-5-nitrobenzene (2-amino-5-nitrophenol) 
CONCLUSION 
Hair dyes which are acceptable for use in cosmetic products 
1,3-di aminobenzene (m-phenylenediamine) 
1-methy1-2.5-diaminobenzene (2,5-diaminotoluene) 
1j 4-diaminobenzene (p-phenylenediamine) 
Hair dyes which are temporarily acceptable for use in cosmetic products 
unti I 31 december 1985 
1-methoxy-2j 4-di ami nobenzene (2j 4-di ami no-ani sole) 
1-methoxy-2,5-diaminobenzene (2,5—di amino-anisole) 
1,2-diamino-4-nitrobenzene (4 NOPD) 
1-hydroxy-2-amino-4-nitrobenzene (2-amino-4-nitrophenol) 
1-hydroxy-2-amino-5-nitrobenzene (2-amino-5-nitrophenol) 
1 -
Hair dyes the use of which should be discontinued 
1-methyl-2,4-diaminobenzene (2,4-diaminotoluene) 
1,4-diamino-2-nitrobenzene (2 NPPD) 
1,2-diaminobenzene (o-phenylenediamine) 
BACKGROUND 
1. Article 12 of the Council Directive 76/768/EEC concerning the approxi-
mation of the laws of the Member States relating to cosmetic products 
enables Member States to prohibit provisionally the marketing of a cos-
metic product in its territory or subject it to special conditions if it 
notes, on the basis of a substantiated justification, that this product, 
although complying with the requirements of the Directive, represents a 
hazard to health. 
2. On the basis of this Article and with reference to available scientific 
data, certain or several Member States have prohibited the following 
substances as hair dyes: 
1-methoxy-2,4-diaminobenzene (2,4-diamino-anisole) 
1-methoxy-2j 5-diaminobenzene (2,5-diamino-aniso le) 
1,4-diamino-2-nitrobenzene (2 NPPD) 
1j2-diamino-4-nitrobenzene (4 NOPD) 
1-methy 1-2,4-diaminobenzene (2,4-di ami no-toluene) 
1-methyl-2,5-diaminobenzene (2,5-diami no-toluene) 
1,2-diaminobenzene (o-phenylenediamine) 
1,3-diaminobenzene (m-phenylenediamine) 
1,4-diaminobenzene (p-phenylenediamine) 
1-hydroxy-2-amino-4-nitrobenzene (2-amiro-4-nitrophenol) 
1-hydroxy-2-amino-5-nitrobenzene (2-amino-5-nitrophenol) 
3. Consequently, the Committee was called to give an opinion on this use. 
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DISCUSSION 
4. The Committee is of the opinion that a conclusion as regards the safe 
use of hair dyes cannot be reached merely on the basis of the results of 
mutagenicity tests, which are of value only as an indication. 
5. Three decisive criteria were selected for the purposes of evaluating the 
toxicity of oxidizing colouring agents: 
- the results of mutagenicity tests; 
- the results of carcinogenicity tests on animals; 
- percutaneous resorption, possibly associated with systemic toxicity. 
The sensitizing potential of these substances was not included in the 
evaluation, since dermatologists have established that this effect is 
rarely observed in practice. 
6. By analogy with certain medicinal products, the Committee considers that 
the use of nitrobenzene derivatives in cosmetics may possibly be asso-
ciated with a risk of haematological toxicity. 
The frequency of disorders in man caused by the consumption of such drugs 
is low (approximately 1/10 000), but the anomalies observed (agranulocy-
tosis, aplasia, anaemia, etc.) are serious and not uncommonly prove to 
be fatal. 
7. In the case of oxidizing colouring agents whose use is provisionally 
maintained, the Committee recommends that the following implementing 
measures be adopted: 
1. the provisional authorization shall not exceed five years; 
2. the Committee shall be kept informed of the status of work with a 
view to an annual appraisal. 
8. In the case of all hair dyes for domestic use, the Committee recommends 
that there should be a warning label with the following indications: 
- "for external use only"; 
- "wash hands after use". 
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9. The Committee recommends that constant attention be paid to epidemio-
logical studies and that all activities along these lines be encouraged. 
10. 1 -met hoxy-2,,4-di ami nobenzene 
10.1 C.I : 76.050 
10.2 Structural formula: 
0CH 
C, H 1 0 N20 
10.3 Synonyms: 2.,4-diaminoanisole 
4-methoxy-m-phenylenediamine. 
10.4 Among a large number of mutagenicity studies, no positive effects 
were seen in the dominant lethal test, micronucleus test, yeast 
and fungi, with questionable effects in cellular lines and positive 
effects with bacteria and drosophila. 
10.5 The oxidized product can be absorbed through the skin. After topi-
cal application it has been recovered in the urine of Thesus mon-
keys, rats and humans. In rats, 0.6-1.7 % of the dose applied was 
recovered in the urine, in monkeys 0.025 % and in humans a maximum 
of 0.036 %. 
10.6 Six long-term studies were conducted with 2.4 DAA: one oral study 
in rats and mice and two dermal studies in rats and mice. In the 
4 dermal studies carried out with the formulations, of which 
2.4 DAA was one of the ingredients, no indication of systemic 
toxicity or carcinogenicity was observed. In both oral studies 
carried out with relatively high dose levels, carcinogenicity was 
observed. 
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10.7 Due to low percutaneous resorption of the oxidized product, the 
S.C.C, is in doubt that the results of the latter tests constitute 
sufficient argument in order to predict a carcinogenic risk for man, 
arising from topical application at low concentration. Moreover, 
the S.C.C, does not forsee sufficient reason to ban this substance 
because of the inconsistency of the results from the mutagenicity 
tests. It recommends continued provisional usage and requests the 
repetition of the carcinogenic tests conceived in a more realistic 
manner than the doses which take account of the resorption levels of 
the product. 
11. 1-methoxy-2,5-diaminobenzene 
11.1 C.I : -
11.2 Structural formula: OCH 
C, H10 N20 
11.3 Synonyms: 2,5-diaminoanisole 
2,5-diamino-1-methoxybenzene 
2-methoxy-p-phenylenediamine. 
11.4 With mutagenicity testing a positive reaction is observed in the 
majority of bacterial tests and negative one in the rest. 
11.5 No data are available on percutaneous resorption. 
11.6 A carcinogenicity study was conducted testing the skin of mice 
during 21 months. The results were negative. The results at pre-
sent available of carcinogenicity studies in this compound do not 
provide an adequate basis for the SCC to make an assessment. 
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11.7 The SCC does not have sufficient data available for a final toxico-
Logical assessment of this substance. They wish to obtain additonal 
information concerning percutaneous resorption and possible carci­
nogenicity in animals after dermal application of adequate doses. 
The SCC recommends continued provisional usage. 
12. 1,4-di ami no-2-ni t robenzene 
12.1 C.I : 76070 
12.2 Structural formula: 
C 6 H7 N 30 2 
12.3 Synonyms: 2-nitro-1,4-phenylenediamine 
2-nitro-1,4-benzenediamine 
2-nitro-4-aminoaniline 
2-ni tro-1j4-diaminobenzene 
2-nitro-p-phenylenediamine (2 NPPD) 
o-ηi tΓθ-p-phenylenediamine 
di ami noni trobenzene 
m-nitro-p-phenylenediamine 
o-ni tro-p-phenylenediamine. 
12.4 For mutagenicity the dominant lethal test and micronucleus test 
were negative but positive results were obtained in several bac­
terial and mammalian cell systems. 
12.5 Cutaneous resorption of the oxidized product is relatively slight 
(0,2 % in the skin of monkeys). 
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12.6 Several long-term toxicity studies have been carried out both 
orally and dermally in dogs, rats and mice. In one dermal study 
with among other 0.0015% 2 NPPD, a higher tumour rate was observed 
in only one strain of mice. In an oral study, with relative high 
dose levels, hepatocellular adenomas and carcinomas were observed 
in female mice. In a rat study the incidence of thyroid tumour was 
higher. 
12.7 In view of the positive carcinogenicity findings in animals, at 
the doses used, the SCC recommends that its use might be discon-
tinued. Nevertheless, this decision could be modified because of the 
product's low percutaneous resorption and because the carcinogeni-
city tests by the dermal route were conducted on a mixture of the 
substance and not with 2 NPPD alone. 
13. 1,2—di ami no-4-ni t robenzene 
13.1 C.I : 76.020 
13.2 Structural formula: 
C 6 H7 N 30 2 
13.3 Synonyms: 4-nitro-o-phenylenediamine (4 NOPD) 
2-amino-4-nitroaniline 
4-ni t ro-1,2—di ami nobenzene 
4-nitro-1,2-phenylenediamine 
p-nitro-o-phenylenediamine. 
13.4 From mutagenicity testing: positive reactions were found in most 
bacterial tests and negative reactions in the micronucleus and 
dominant lethal tests. 
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13.5 No data were available on cutaneous resorption. 
13.6 The NCI studies showed that 4 NOPD, administrated daily for two 
years in food was not carcinogenic in either rats or mice. When oxi-
dized 4 NOPD was applied topically to mice over a period of two 
years it did not cause the development of tumours, but when 4 NOPD 
mixed with 2 NPPD was tested, under similar conditions, the develop-
ment of lymphomas and genital carcinomas was observed. 
13.7 In view of the absence of conclusive carcinogenic effects in ani-
mals, the SCC sees no reasons for prohibiting 4 NOPD at present 
but wishes to obtain additional information concerning percutaneous 
resorption and the repetition of more realistic carcinogenicity 
tests and in the meantime it can accept its continuing use on a pro-
visional basis. The implementation of this recommendation will be 
reviewed each year. 
14. 1-methyl-2,4-diaminobenzene 
14.1 C.I : 76.035 
14.2 Structural formula : 
C7 H10 N2 
14.3 Synonyms: 2,4-diaminotoluene 
2,4-diaminobenzene (mTD). 
14.4 The mutagenicity tests are not adequate. Most of the findings so 
far are positive. 
14.5 Percutaneous uptake of the non-oxidized product in the skin of 
monkeys indicate a high level of percutaneous absorption (16-18 %) 
(unpubli shed). 
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14.6 Long-term feeding of rats led to the formation of liver tumours, 
but topical application to mice of the compound was followed by no 
neoplastic changes. 
14.7 On the balance of evidence and in the cause of prudence the SCC 
recommends that the use of mTD should be discontinued pending 
further studies on the percutaneous resorption of this compound 
under conditions of use in accord with those in practice. 
15. 1-methy1-2,5-diaminobenzene 
15.1 C.I : 76.042 
15.2 Structural formula: 
C7 H10 N2 
15.3 Synonyms: 2,5-diaminobenzene 
2j 5-diaminotoluene (pTD) 
p-diaminotoluene 
2-methyl-1.4-diaminobenzene 
4-amino-2-methylaniline 
2-methyl-p-diaminophenylene. 
15.4 From mutagenicity testing: a positive reaction was observed in the 
majority of the bacterial tests, whereas no mutagenic effect was 
observed in the other tests. 
15.5 Percutaneous resorption of the oxidized product is slight (of the 
order of 0.2 % in the skin of rats, dogs and man). 
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15.6 Long-term toxicity studies have shown that oxidized pTD is not 
carcinogenic in rats and mice when administered either orally or 
topically. 
15.7 The SCC recommends continued usage of pTD in view of its low cuta-
neous resorption and the absence of carcinogenic effects. 
16. 1^ .2-di ami nobenzene 
16.1 C.I : 76.010 
16.2 Structural formula: 
C6 H8 N2 
16.3 Synonyms: o-phenylenediamine. 
16.4 The SCC is unable to take a decision on this substance due to 
lack of information. It seems, moreover, that this substance is 
not used. 
17. 1.3—di aminobenzene 
17.1 C.I : 76.025 
17.2 Structural formula: 
C6 H8 N2 
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17.3 Synonyms: n-phenylenediamine. 
17.4 The findings from mutagenicity tests were generally positive with 
bacterial cell lines and negative in such tests as the micronucleus 
and the dominant lethal study. 
17.5 Percutaneous resorption (4 %) of the oxidized product in the skin 
of dogs is high by comparison with that of other oxidized colorants; 
nevertheless, long-term toxicity studies on rodents (orally in the 
case of mPD and topically in the case of oxidized mPD) show no 
evidence of systemic toxicity. 
17.6 Long-term toxicity studies using mPD orally and oxidized in mPD 
incorporated in a formulation and applied topically, showed no 
carcinogenic changes in rats or mice. 
17.7 Not with standing the percutaneous uptake level of 4 % the SCC 
recommends continued usage of mPD in view of the lack of systemic 
long-term toxicity and absence of carcinogenic effects in animals 
with the dose levels tested. 
18. 1,4-diaminobenzene 
18.1 C.I : 76.060 
18.2 St ruc tura l formula: 
C6 H8 N2 
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18.3 Synonyms: p-phenylenediamine 
4-aminoani Line 
p-aminoaniline 
p-diaminobenzene. 
18.4 With the exception of the tests using the oxidized product for 
Escherichia coli, no mutagenic effect has been observed in the so 
far conducted tests. 
18.5 Cutaneous resorption of PPD from the dog is relatively low (1 % ) , 
being ten times lower in the case of oxidized pPD (0.13 % ) . 
18.6 All long-term animal toxicity studies by the topical and oral 
routes indicate that pPD is not carcinogenic. 
18.7 Epidemiological data indicate that there is no evidence of a car-
cinogenic effect in man. 
18.8 On the basis of the low cutaneous resorption, the lack of carcino-
genic effects in animals and the epidemiological data, which 
suggest that this compound does not constitute a danger to human 
health, the SCC recommends continued usage of paraphenylenediamine. 
19. 1-hydroxy-2-amino-4-nitrobenzene 
19.1 C.I : 76.530 
19.2 Structural formula: 
C6 H6 N2°3 
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19.3 Synonyms: 2-amino-4-nitrophenol. 
19.4 The findings from mutagenicity tests were generally positive with 
bacterial cell lines and negative in such tests as the micronucleous 
and the dominant lethal study. 
19.5 Percutaneous absorption: the oxidized product is absorbed under 2 % 
by the skin of dogs. 
19.6 The only test for carcinogenicity was skin painting experiments on 
mice for 21 months. As far as can be judged, the results were nega-
tive, but in view of some unsatisfactory features of the study, it 
is difficult to draw firm conclusions for the findings. 
19.7 The SCC has insufficient data for a carcinogenic assessment of this 
substance and wishes to obtain additional information concerning car-
cinogenicity in animals after dermal application of adequate doses. 
However, it sees no reason to forbid its continued provisional use 
of the 2-amino-4-nitrophenol. 
20. 1-hydroxy-2-amino-5-ni trobenzene 
20.1 C.I : 76.535 
20.2 Structural formula: 
20.3 Synonyms: 2-amino-5-nitrophenoL. 
C6 H6 N2°3 
- 13 -
20.4 The findings from mutagenicity tests were generally positive with 
bacterial cell lines and negative in such tests as the micronucleus 
and the dominant lethal study. 
20.5 No data are available on cutaneous resorption. 
20.6 A carcinogenicity study was conducted testing the skin of mice 
during 21 months. The results were negative. The results at present 
available of carcinogenicity studies in this compound do not pro-
vide an adequate basis for the SCC to make an assessment. 
20.7 The SCC does not have sufficient data available for a conclusive 
toxicological assessment of this substance. The wish to obtain 
additional information concerning percutaneous resorption and 
possible carcinogenicity in animals after dermal application of 
adequate doses. However, it sees no reason to forbid its continued 
provisional use. 
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REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY ON THE USE 
OF 1,3-BIS (HYDROXIMETHYL) IMIDAZOLIDINE-2-THIONE IN HAIR-CARE 
PREPARATIONS 
(Opinion delivered on 2 September 1980) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give an opinion on the use in hair-care preparations of 
1,3-bis (hydroxymethyl) imidazolidine-2-thione in a maximum concentration 
of 2% in the finished cosmetic product and under the conditions laid down 
in Directive 76/768/EEC. 
CONCLUSION 
The Committee is of the opinion that the use of 1,3-bis (hydroxymethyl) 
imidazolidine-2-thione represents no hazard to health under the conditions 
Laid down in Directive 76/768/EEC provided that the use of this 
substance is limited to hair-care products with an acid pH. 
BACKGROUND 
1. Article 5 of Council Directive 76/768/EEC on the approximation of 
the laws of the Member States relating to cosmetic products, as amended 
by Directive 79/661/EEC, obliges Member States to permit, up to 
31 December 1980, the marketing of cosmetic products containing 1,3-bis 
(hydroxymethyl) imidazolidine-2-thione under the following conditions : 
Field of Maximum authorised Other Conditions of use and 
application concentration in limitations warning which must be 
and/or use the finished and printed on the label 
cosmetic product requirements 
Hair-care (a) up to 2% 
preparations 
(b) from 2% to 
8% 
(a) 
Prohibited 
in aerosol 
dispensers 
(b) ditto 
(a) Contains 1,3-bis 
(hydroxymethyl) 
imidazolidine-2-thione 
(b) Rinse hair 
thoroughly after use 
Contains 1,3-bis 
(hydroxymethyl) 
imidazolidine-2-
thione 
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2. As from 1 January 1981, this substance will have to be : 
either 
- definitively permitted 
or 
- definitively prohibited 
or 
- provisionally retained for a further period 
or 
- deleted from all Annexes to the Directive. 
3. Concentrations of between 2% and 8% are no longer employed. 
4. Consequently the Committee is requested to deliver an opinion on the 
use of 1,3-bis (hydroxymethyl) imidazolidine-2-thione in hair-care 
preparations in a maximum concentration of 2% in the finished product and 
under the conditions laid down in Directive 76/768/EEC,i.e. by means of 
- prohibition of the use of the product in aerosol dispensers (sprays) and 
- a warning, which must be printed on the label. 
DISCUSSION 
5. Acute toxicity studies using the oral route in mice and rats show 
that 1,3-bis (hydroxymethyl) imidazolidine-2-thione (DHMT) is of low 
toxicity. 
6. DHMT is well tolerated by the skin, even after repeated application, 
and by the mucous membranes at the pH for cosmetic use (pH/3) while no 
sensitizing properties have been observed in rabbits and guinea pigs. 
These observations have been confirmed in man. 
7. Percutaneous absorption is low (1.1% - calculated in the case of human 
skin) and the greater part of the quantity absorbed is rapidly excreted. 
Furthermore, given its considerable affinity for hair, it has been 
ascertained that only 2% of the quantity applied can come into contact 
with the scalp. 
8. During in vitro mutagenicity studies no mutagenic effect, with or 
without microsomial activitation, has been observed. 
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9. Although certain imperfections in the way the tests were 
conceived and the way in which they were carried out have been noted, 
the long-term toxicity studies using the oral and topical routes in 
mice have shown no indication of carcinogenicity due to DHMT. 
10. During acute toxicity studies, using the intraperitoneal route 
in rats, and subacute toxicity studies, entailing repeated topical 
administration in rats, under experimental conditions corresponding 
to doses considerably higher than for human use, no significant 
variation in serum contents thyroid hormones has been observed. 
11. The structural difference between DHMT (Tetrasubstituted 
thiourea)and its homopolymers, on the one hand, and ethylene thiourea, 
thiourea, on the other, must be noted. This difference is due to 
the fact that there is no H atom in an opposition to the double bond 
in the group C = S / implying that the tautomeric form - SH -, 
present in known products exhibiting thyrostatic activity, 
cannot react. 
12. Cosmetic use requires DHMT to polymerize at an acid pH and 
it decomposes into ethylene thiourea only at an alkaline pH. 
13. In view of: 
- the low percutaneous absorption of DHMT and the small quantities 
actually absorbed by the scalp during cosmetic use; 
- the absence of any mutagenic effect; 
- the absence of evidence of carcinogenicity in mice; 
- the absence of any variation in thyroid hormones contents during 
acute and subacute toxicity studies in rats, 
the Committee considers that this is a substance which does not 
represent any hazard to health under the conditions laid down 
in Directive 76/768/EEC provided that the use of DHMT is limited to 
hair-care products with an acid pH. 
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SUPPLEMENTARY OPINION ON BORIC ACID 
(Opinion expressed 28 June I982) 
Pursuant to point 11 of its opinion given on 22 May 1979 (l)t "the Committee 
has examined the new information "brought to its attention. 
1. - From a study to determine the boron content of the blood after the 
application of a water emulsifying ointment with 3$ "boric acid to the 
skin of newhorn "bah ie s (2), it was found that the amount of "boron in 
the "blood of these babies does not change. 
- Nor has any correlation been observed between the toron concentration 
of the mother's milk and the amount of boron in the blood of newborn 
babies. 
- On the other hand, large individual variations were observed and the 
highest blood boron contents were found in the control group which was 
not studied at the same time as the test group. 
2. - From a study of the urinary excretion of boron after the application 
of a water emulsifying ointment with 3% of boric acid to healthy and 
to damaged skin in adults (3), it was found that the urinary excretion 
of boron is unaffected, whatever the state of the skin. 
- It is observed that the total boron excreted during the 24 hours prior 
to the application of the emulsion is significantly higher than the 
total boron excreted during the days following the application. 
- The measurement of urinary excretion gives no information on any 
absorption by organs and tissues matter. 
- Very large individual differences and daily fluctuations in boron 
content, which probably depend on diet, were observed but not taken 
into account in the course of the study, thus reducing its degree of 
accuracy. 
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3. - In a parallel study carried out with a hydro gel with }>% boric acid (3), 
a large increase in the boron contents of the blood and urine was 
observed after application. This proves that the percutaneous penetra-
tion of boric acid depends on the nature of the vehicle« 
4. - In a new study (4) on oral absorption and on elimination in man, no 
accumulation of boric acid was observed. 
In fact, 93/0 of the quantity ingested (750 to 1 5OO mg) was excreted 
in the urine, with an estimated half-life of I5 to 20 hours. 
There was no significant difference between the urinary excretion of 
boric acid following ingestion of an aqueous solution and that follo-
wing application of an ointment with a continuous oily phase. 
5. - A comparative in vitro test (5) showed that the release of boric acid 
from the ointment was slight in the case of a few commercial prepara-
tions with a continuous oily phase. 
As a result of this new information, the Committee has revised the 
conclusions of its opinion of 22 May 1979· It feels that there is 
no need to amend them in the case of talcs and products for oral hygiene. 
In the case of the other products, however, since the nature of the 
vehicle can affect the percutaneous penetration of boric acid, the 
Committee still considers that the warning "Not to be used on damaged 
skin" should , as a matter of prudence, appear on the labels, unless 
it has been clearly established that there is no risk of boric acid 
absorption, as in the case of the water emulsifying ointment (6). 
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(2) B.F. HANSEN, B. AGGERBECK, J.A. JANSEN 
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REPORT OF THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
CONCERNING THE USE OF 4,4- DIMETHYL-1,3-OXAZOLIDINE 
AS A PRESERVATIVE 
(Opinion delivered on 28 June 1982) 
TERMS OF REFERENCE OF THE COMMITTEE 
To deliver its opinion on the use of 4,4- dimethyl-1,3-oxazolidine as a 
preservative with a maximum concentration in rinse-off cosmetic products 
of 0.1% of an aqueous solution containing 78% of the active substance. 
CONCLUSION 
The Committee considers that : 
(a) additonal information on mutagenesis is needed; 
(b) a study should be carried out on short-term oral toxicity with doses 
that are sufficient to produce a systemic effect; 
(c) unless, in the normal conditions of use, percutaneous absorption 
is insignificant, a teratogenicity study should be carried out, 
in view of the fact that percutaneous absorption in animals appears 
to be substantial. 
However, on the basis of the data available, the Committee could accept, 
for the time being, the use of 4,4-dimethyl-1,3-oxazolidine as a preserva-
tive in cosmetic products on a provisional basis under the above conditions. 
BACKGROUND 
1. Council Directive 76/768/CEE on the approximation of the laws of the 
Member States relating to cosmetic products, as last amended by Council 
Directive 82/368/EEC, allows those cosmetic products to be placed on 
the market that contain as preservatives only the substances listed in 
Annex VI to the Directive within the specified limits and concentrations. 
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2. The industry has requested that 4,4 - dimethyl-1,3-oxazolidine be entered 
on the list in Annex VI and has submitted scientific documentation in 
support of its request. 
3. The Committee is therefore invited to deliver an opinion on the use of 
4,4—dimethyl-1,3-oxazolidine as a preservative with a maximum concen-
tration in rinse-off cosmetic products of 0.1% of an aqueous solution 
containing 78% of the active substance. 
DISCUSSION 
4. Chemical name (IUPAC): 4,4—dimethyl-1,3-oxazolidine 
CH, 
H3C C -CH. 
l Í 
C5H11N0 
Generic name: dimethyl oxazolidine 
5. Dimethyl oxazolidine is marketed in the form of an aqueous solution con-
taining 78-87.4% of active igredients. 
6. Dimethyl oxazolidine is used as a preservative in rinse-off cosmetic 
products with a maximum concentration in the finished product of 0.1% 
of the commercial solution. 
7. Both the acute oral and acute dermal toxicity are moderate. The oral 
LDt-0 in the rat is about 950 mg/kg. No signs of toxicity were noted at 
400 mg/kg. The dermal LD 5 Q in the rabbit is estimated at 970-2000 mg/kg. 
The animals developed progressive injury to the skin with eschar forma-
tion. In view of the fact that acute dermal toxicity is just as 
severe as acute oral toxicity, it would appear that considerable 
percutaneous absorption of the substance occurs. 
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8. An 87.4% solution was severely irritating to the rabbit eye and the changes 
produced showed no recovery over 72 hours. Dilutions of 1000 ppm and 
5000 ppm of the commercial solution (equal to 0.08% and 0.4% of dimethyl-
oxazolidine) were not irritant to the eye. 
9. In rabbits, a primary skin irritation test, using 0.5 ml of the 87.4 % aqueous 
solution, with and without occlusion caused slight to severe signs of oedema, 
erythema and deep tissue reaction. 
10. The compound shows skin sensitising properties in the guinea-pig. These 
were not found in the rabbit. In a well-conducted study in 101 human 
volunteers no evidence of sensitisation was found in repeated tests with 
a 3% aqueous solution. 
11. A sub-chronic 13-week dermal toxicity test in rats at dose levels of 0, 
1.95, 19.5, and 195 mg/kg in a 1:1 ethanol/water solution induced in-
creased haematopoietic activity in the top dose group, as well as severe 
skin irritation. No other treatment-related abnormalities were found 
despite extensive clinical, chemical and histological examination. 
12. The Ames test showed a reproducible dose-related increase in revertants 
in two of five strains, which was not regarded as significant by the in-
vestigators. 
13. It should be noted that this is a nitrostable compound. 
14. Thus, the Committee considers that 
a) additional information on mutagenesis is needed; 
b) a study should be carried out on short-term oral toxicity with doses 
that are sufficient to produce a systemic effect; 
c) unless, in the normal conditions of use, percutaneous absorption 
is insignificant, a teratogenicity study should be carried out, 
in view of the fact that percutaneous absorption in animals appears 
to be substantial. 
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15. However, on the basis of the data available, the Committee could accept, 
for the time being, the use of 4,4- dimethyl-1,3-oxazolidine as a pre-
servative in rinse-off cosmetic products with a maximum concentration 
in the finished cosmetic product of 0.1% of an aqueous solution con-
taining 78% of the active substance. 
16. Reference: COLIPA dossier. 
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REPORT OF THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
CONCERNING THE USE OF 1,2-DIBROMQ- -2,4-DICYANOBUTANE AS A PRESERVATIVE 
(Opinion delivered on 28 June 1982) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give an opinion on the use of 1,2-dibromo-2,4-dycyanobutane as a 
preservative at a maximum concentration of 0.1% in the finished cosmetic 
product. 
CONCLUSION 
The Committee wishes to obtain information on the effects of 1,2-dibromo-
2,4- dicyanobutane on the thyroid gland, with the specific aim of 
establishing the no-effect dose. On the basis of the existing data, 
however, it can approve the provisional use of 1,2-dibromo-2,4-
dicyanobutane as a preservative in cosmetics at a maximum concentration 
of 0.1% in the finished product. 
BACKGROUND 
1. Council Directive 76/768/EEC on the approximation of the laws of the 
Member States relating to cosmetic products, as last amended by 
Council Directive 82/368/EEC, authorizes the placing on the market of 
cosmetic products containing as a preservatives only the substances 
listed in Annex VI to the said directive, within the limits and 
concentrations specified therein. 
2. The industry has requested that 1,2-dibromo-2,4-dicyanobutane be added 
to that Annex and has submitted a scientific dossier in support of its 
request. 
3. The Committee is consequently invited to express an opinion on the use 
of 1,2-dibromo-2,4-dicyanobutane as a preservative at a maximum 
concentration of 0.1% o, the finished cosmetic product. 
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DISCUSSION 
4. Chemical name : 1,2-Dibromo-2,4-dicyanobutane 
H Br H H > ι Ι ι B r - C - C - C - C - H 
I I I I 
H CN H CN „ ,, M „ 
C6 H6 N2 B r2 
5. Solubility in water 0.27% at 0° easely soluble in organic solvents. 
6. Used in cosmetics up to 0,1%. 
7. The substance possesses moderate acute toxicity upon oral and low 
toxicity upon dermal and inhalation exposure. 
8. It is severely irritating to the eye and moderately irritating to 
the skin if applied undiluted, but no irritation of the skin or the 
eye of rabbits and the human skin is observed in a dilution of 0.1% 
as used in practice. A 0.3% dilution in oil was neither irritating 
nor sensitizing when applied to the human skin. 
9. An oral dose (50 mg/kg) given to rats, was mainly excreted in the 
urine (84-91%). A small part was excreted in the faeces (6-10%) 
and a very small part in the respiration air (0.5%). Seven days after 
a single intragastric dose 0.4% remained in the organs, 0.3% of the 
dose was in the liver. 
10. In a 90-day study, dietary levels of 0 (control), 83.5, 500 or 3000 ppm 
given to the offspring of rats which had already been fed these 
diets through the muting, pregnancy and lactation periods, increased 
the weight of the tyroid in the top-dose group; growth rate was 
significantly lower for the mid- and high-dose males. Microscopically, 
increased haematopoieses was observed in the spleen of the top-dose 
females. No diseased or malformed pups were seen in the litters 
of the parent rats, which suggests abscence of teratogenic 
properties. 
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11. A 90-day study in dogs with feeding levels of 0 (control), 167, 
1000 or 4000 ppm showed several changes in the top-dose group, 
such as changes in body weight, haematology, blood biochemistry, 
enlarged thyroids (hyperplasia) and increased haematopoieis in the 
liver and spleen. Clinically the dogs of the highest dose showed 
inter alia diarrhoea. 
12. The lowest feeding level (4.2 mg/kg body weight/day) was a no-toxic-
effect in the rat and possibly also in the dog. 
13. The Ames test (with or without activation), and a dominant lethal 
assay in male mice were negative. 
14. The Committee requests informations on the effects of the compound 
on the function of the thyroid specially with regard to establishing 
the no-effect level. On the base of the existing data, however, it 
can approve the provisonal use of 1,2-dibromo-2,4-dicyanobutane as 
a preservative in cosmetics at a maximum concentration of 0,1% in 
the finished product. 
Ref. : COLIPA file. 
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